Home > Oncology > ASCO 2020 > Genitourinary Cancer > Maintenance olaparib improves OS in relapsed ovarian cancer with BRCA1/2 mutation

Maintenance olaparib improves OS in relapsed ovarian cancer with BRCA1/2 mutation

In patients with platinum-sensitive relapsed ovarian cancer harbouring BRCA1/2 mutation, final overall survival (OS) results from the phase 3 SOLO2/ENGOT-ov21 trial showed significant benefit for patients receiving maintenance treatment with olaparib over placebo.

Prof. Andrés Poveda (Hospital Quironsalud, Spain) presented the results, after approximately 5 years of follow-up [1]. The trial enrolled patients with a *BRCA* mutation with relapsed high-grade serous ovarian cancer or endometrioid cancer. Patients had received at least 2 prior lines of platinum-based chemotherapy and were in a complete or partial response.

Participants were randomised to receive 300 mg olaparib twice daily (n=196) or placebo (n=99), and treatment continued until disease progression occurred, with a median follow-up of 65.7 months in the olaparib arm and 64.5 months in the placebo arm. The primary endpoint was ...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on